pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. In 2019 the Danish company also licensed a preclinical-stage, small-molecule candidate for NASH from Japan’s UBE.

Gene Silencing 65

Gene Silencing Gene RNA Contract Manufacturing 65

The Pharma Data

MARCH 22, 2022

Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Production 52

Pfizer

DECEMBER 13, 2021

In separate countries, joined by a common purpose, they worked to formulate lipid nanoparticles - a notoriously tricky process - that would protect and guide the mRNA, which programs cells to produce antibodies to fight off COVID-19 by introducing a protein found on the surface of the virus. Understanding mRNA COVID-19 Vaccines.

Manufacturing 52

Manufacturing Vaccination Vaccine Production 52

Drug Discovery World

SEPTEMBER 6, 2022

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. Despite this the industry is still expanding. New indications . Workforce .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52